ALS

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study

New Stage III biomarker data in people with ALS validates NeuroSense's clinical strategy, the company reports.

ALS

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for ALS

ProMIS Neurosciences Inc announces new milestones in potential therapeutic approaches for ALS, the company notes in a media release.

ALS

Clene Nanomedicine Presents Updated Clinical Data at MDA Conference

Clene Nanomedicine Inc presents results from Phase 2 RESCUE-ALS and REPAIR trials and preclinical data in ALS at the 2022 MDA Conference.

Meta-Analysis Explores Potential Environmental Causes of ALS

by Debbie Overman | Jan 28, 2022 | ALS

In a new meta-analysis of available ALS literature, Arizona State University researchers explore environmental influences potentially linked to ALS. The study also examines the distribution of ALS over space and time.

Clinical Trial Tests Promising ALS Therapy

by Debbie Overman | Jan 26, 2022 | ALS

An experimental drug, first tried as a last-ditch effort to help a 25-year-old woman with juvenile ALS, is now being tested in ALS patients in a global, phase 3 clinical trial.

Comcast and Team Gleason Partner on Xfinity Adaptive Remote

by Debbie Overman | Jan 19, 2022 | ALS, Home & Daily Living

Comcast and Team Gleason have partnered to drive inclusive innovation to improve the independence and quality of life for people with physical and speech disabilities, including those living with ALS, they report.

New Study Finds NFL Players Four Times More Likely to Die of ALS

by Debbie Overman | Jan 5, 2022 | ALS, Research

“It has become clear that years of repeated impacts to the head can cause the human brain to break down along many pathways,” The Hill reports.

Biden Says Bipartisan Legislation Funding ALS Research ‘Represents the Spirit of the Season’

by Debbie Overman | Dec 30, 2021 | ALS

President Joe Biden [recently] signed into law bipartisan legislation that expands funding for amyotrophic lateral sclerosis research, hailing it as in “the spirit of the season,” CNN reports.

Tel Aviv University Breakthrough Touted as Key to Reversing ALS

by Debbie Overman | Dec 30, 2021 | ALS, Research

Israeli researchers announced [recently] that they have uncovered a key mechanism that causes the neurodegenerative disease ALS, which may unlock a way to delay or reverse the condition which affects thousands of people annually, The Times of Israel reports.

Man With ALS Sends First-Ever Tweet Using Thoughts And Brain-Computer Interface

by Debbie Overman | Dec 29, 2021 | ALS

A paralyzed man has tweeted a message out to the world using his thoughts through a brain-computer interface, IFL Science reports.

Alzheimer’s Drug Discovery Foundation and Target ALS Partner to Accelerate Biomarker Discovery and Development

by Debbie Overman | Dec 22, 2021 | ALS, Neurological

The Alzheimer’s Drug Discovery Foundation and Target ALS announce a new partnership to identify and develop biomarkers for neurodegenerative diseases, including Alzheimer’s disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Degeneration.

Detailed Images of Molecule Associated with ALS Could Open Door to Therapies

by Debbie Overman | Dec 13, 2021 | ALS, Research

Scientists have determined the structure of the molecule associated with amyotrophic lateral sclerosis (ALS) and multiple other neurodegenerative diseases, they suggest, in Nature.

Three Leading ALS Organizations Celebrate House Passage of ACT for ALS, Call for Swift Senate Action

by Debbie Overman | Dec 10, 2021 | ALS, Association News

I AM ALS, The ALS Association and the Muscular Dystrophy Association released the following statement on the recent passage of ACT for ALS in the House of Representatives:

ALS Therapy Should Target Brain, Not Just Spine

by Debbie Overman | Dec 6, 2021 | ALS

The brain is indeed a target for treating ALS (amyotrophic lateral sclerosis), Northwestern Medicine scientists discover, according to research published in Gene Therapy.

Altered Fat Metabolism, Enzyme, Plays Key Role in Lou Gehrig’s Disease, Per Study

by Debbie Overman | Nov 18, 2021 | ALS, Research

A new study using genetically engineered mice and human cell and tissue samples has added to evidence that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis (ALS), the neuromuscular disorder also known as Lou Gehrig’s disease.

Doing This Points to Potential ALS Treatment

by Debbie Overman | Nov 15, 2021 | ALS, Research

Blocking tau, a hallmark of Alzheimer’s disease, may benefit patients with amyotrophic lateral sclerosis (ALS), researchers suggest.

Does a Lifetime of Vigorous Exercise Increase the Risk of Developing ALS?

by Debbie Overman | Oct 22, 2021 | ALS

There is debate over whether vigorous physical activity is a risk factor for amyotrophic lateral sclerosis (ALS). A new study published in Neurology suggests it depends on whether that vigorous activity you get over your lifetime happens on the job or during leisure time.